EG229862 Inhibitors
Gm4861, with its predicted function of enabling ubiquitin protein ligase binding activity and involvement in proteasome-mediated ubiquitin-dependent protein catabolic processes, plays a pivotal role in maintaining cellular protein homeostasis. Functioning in both the cytoplasm and nucleus, Gm4861 is intricately involved in the regulation of protein turnover, specifically targeting ubiquitinated proteins for degradation through the ubiquitin-proteasome system (UPS). This critical role positions Gm4861 as a key player in preventing the accumulation of misfolded or unwanted proteins, ensuring cellular functionality and integrity.
Inhibition of Gm4861 involves a multi-faceted approach, reflecting the complexity of the cellular processes it governs. Direct inhibition can be achieved through the use of proteasome inhibitors, such as those interfering with the chymotrypsin-like activity of the 26S proteasome. By disrupting the normal functioning of the UPS, these inhibitors impact Gm4861's ability to regulate ubiquitin-dependent protein degradation. Furthermore, indirect inhibitors target upstream processes like endoplasmic reticulum-associated protein degradation (ERAD) and protein folding. These compounds indirectly influence Gm4861 by altering the availability of substrates for its catabolic processes, leading to a disturbance in the delicate balance of cellular protein homeostasis. The intricate regulatory network surrounding Gm4861 highlights its significance in orchestrating a finely tuned system for maintaining cellular proteostasis through the selective degradation of proteins marked for disposal.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that directly impedes protein degradation by blocking the 26S proteasome, preventing ubiquitin-proteasome system (UPS)-mediated protein catabolism. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A dipeptidyl boronic acid derivative inhibiting the chymotrypsin-like activity of the proteasome. Directly disrupts protein degradation and the UPS, influencing Gm4861's predicted role in the regulation of proteolysis. | ||||||
NMS-873 | 1418013-75-8 | sc-478803 | 5 mg | $300.00 | ||
Inhibitor of p97 ATPase, a critical component in endoplasmic reticulum-associated protein degradation (ERAD). Indirectly impacts Gm4861 by disrupting the process that regulates the availability of substrates for proteasome-mediated ubiquitin-dependent protein catabolic processes. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Indirect inhibitor disrupting endoplasmic reticulum (ER) homeostasis and autophagy. Impacts Gm4861 by influencing ER stress response pathways and protein quality control mechanisms, indirectly affecting the substrates available for UPS-mediated protein degradation. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Inhibitor of NEDD8-activating enzyme (NAE), disrupting the NEDDylation pathway. Affects Gm4861 by indirectly modulating the ubiquitin-proteasome system and the availability of ubiquitinated proteins targeted for degradation. | ||||||
YODA 1 | 448947-81-7 | sc-507361 | 10 mg | $215.00 | ||
Disrupts the deubiquitination process by inhibiting the deubiquitinase activity of USP7. Indirectly influences Gm4861 by altering the balance of ubiquitinated proteins and interfering with the normal turnover regulated by the ubiquitin-proteasome system. | ||||||
P005091 | 882257-11-6 | sc-478535 | 10 mg | $155.00 | ||
Inhibitor of ubiquitin-specific protease 7 (USP7). Indirectly impacts Gm4861 by interfering with deubiquitination, a key step in the regulation of protein degradation and turnover through the ubiquitin-proteasome system. | ||||||
AT-101 | 90141-22-3 | sc-507316 | 10 mg | $160.00 | ||
Pan-Bcl-2 inhibitor indirectly impacting Gm4861 by interfering with the anti-apoptotic Bcl-2 family proteins. Affects cellular processes that may lead to altered ubiquitination patterns and protein degradation, indirectly influencing Gm4861's role in proteasome-mediated catabolic processes. | ||||||
JNJ 26854165 | 881202-45-5 | sc-364514 sc-364514A | 5 mg 25 mg | $171.00 $577.00 | ||
Inhibitor of heat shock protein 90 (Hsp90), impacting protein folding and degradation pathways. Indirectly influences Gm4861 by altering the stability of proteins involved in the ubiquitin-proteasome system, affecting the availability of substrates for Gm4861-mediated catabolic processes. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $77.00 $188.00 $431.00 | 1 | |
Broad-spectrum deubiquitinase (DUB) inhibitor, impacting multiple DUBs. Indirectly influences Gm4861 by disrupting deubiquitination processes, altering the ubiquitin-proteasome system, and impacting the availability of ubiquitinated proteins targeted for degradation. | ||||||